Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

laree2

What can previous outbreak modeling tell us about the COVID-19 pandemic?

May 11, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Interview, coronavirus, feature, pharma

Dr LaRee Tracy, a lecturer at San Diego State University and Director of Biostatistics at PHASTAR, led a team of …
Feature
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020 Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
News
nhs_doctors

Latest large hydroxychloroquine study suggests it does not help treat COVID-19

May 11, 2020 Sales and Marketing COVID-91, coronavirus, hydroxychloroquine

The results of another study into the use of hydroxychloroquine in COVID-19 patients has cast further doubts on its effectiveness …
News
fda2outsideweb

Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer

May 11, 2020 Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer

Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …
News
fda

Eli Lilly’s Retevmo approved by FDA to treat lung and thyroid cancers

May 11, 2020 Sales and Marketing COVID-19, coronavirus

The FDA has announced that Retevmo (selpercatinib) has been approved to treat both non-small-cell lung cancer (NSCLC) and medullary thyroid …
News
trial

NIAID announces the launch of second remdesivir trial for COVID-19 patients

May 11, 2020 Sales and Marketing COVID-19, coronavirus, niaid, remdesivier

The US National Institute of Allergy and Infectious Diseases (NAID) has announced that it is enrolling COVID-19 patients in hospital …
News

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020 Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …
News

FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14

May 7, 2020 Sales and Marketing Incyte, Novartis, Tabrecta, pharma

The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small …
News
fda2outsideweb

AZ’s Farxiga becomes first FDA-approved SGLT2 inhibitor for heart failure with reduced ejection fraction

May 6, 2020 Research and Development, Sales and Marketing AstraZeneca, FDA, farxiga, heart failure

The FDA has moved to approve an oral tablet formulation of AstraZeneca’s Farxiga (dapagliflozin) to reduce the risk of cardiovascular …
News
partnership

Portola Pharmaceuticals to merge with Alexion in $1.41bn cash deal

May 6, 2020 Research and Development, Sales and Marketing Alexion, Portola Pharmaceuticals, pharma

Alexion has announced it is to acquire Boston-based blood disorder specialist Portola Pharmaceuticals in a transaction to the value of …
News
kim_stratton_orphazyme

Working Life Interview: Kim Stratton, CEO, Orphazyme

May 4, 2020 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Interview, Orphazyme, Working Life

“Every professional faces challenges. As a woman in industry, particularly in leadership, it adds another dimension to those challenges in …
Feature
flu_shot_2019

Lonza and Moderna enter agreement to mass produce coronavirus vaccine

May 4, 2020 Sales and Marketing COVID-19, coronavirus

Lonza Group AG and Moderna Inc have entered a deal to develop 1 billion doses of coronavirus vaccines a year. …
News
gilead-sciences

FDA approves emergency use of Gilead’s remdesivir for hospitalised COVID-19 patients

May 4, 2020 Sales and Marketing COVID-19, FDA, Gilead, coronavirus, remdesivir

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one …
News
trumpy

Trump vows to reduce America’s reliance on foreign drug imports

May 4, 2020 Sales and Marketing COVID-19, coronavirus

President Donald Trump has vowed to cut the US’s reliance on foreign drugs, singling out China and Ireland as countries …
News
korean_1

UK testing experimental treatment for use in COVID-19 patients

May 4, 2020 Sales and Marketing COVID-19, coronavirus, coronavirus treatment

British scientists are testing an experimental drug to help some of society’s most vulnerable fight off the COVID-19 coronavirus.
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026